Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022;92(6):1005-1010.
doi: 10.1134/S1070363222060123. Epub 2022 Jun 20.

Interaction of 5-[4'-(N-Methyl-1,3-benzimidazol-2-yl)phenyl]-10,15,20-tri-(N-methyl-3'-pyridyl)porphyrin Triiodide with SARS-CoV-2 Spike Protein

S A Syrbu  1 , A N Kiselev  1   2 , M A Lebedev  1   2 , Yu A Gubarev  1 , E S Yurina  1 , N Sh Lebedeva  1
Affiliations

Interaction of 5-[4'-(N-Methyl-1,3-benzimidazol-2-yl)phenyl]-10,15,20-tri-(N-methyl-3'-pyridyl)porphyrin Triiodide with SARS-CoV-2 Spike Protein

S A Syrbu et al. Russ J Gen Chem. 2022.

Abstract

The results of experimental studies of the interaction of the S-protein with a monohetaryl-substituted porphyrin containing a benzimidazole residue are presented. It has been revealed that the S-protein forms high-affinity complexes with the specified porphyrin. The porphyrin binding by the SARS-CoV-2 S-protein has proceeded stepwise; at the first stage, the driving force of the complexation is electrostatic interaction between the surface negatively charged regions of the protein and cationic substituents of the porphyrin. At the second stage, the target complex of the S-protein with the porphyrin is formed. It has been established that the introduction of 5-[4'-(N-methyl-1,3-benzimidazol-2-yl)phenyl]-10,15,20-tri-(N-methyl-3'-pyridyl)porphyrin triiodide into a solution of the S-protein complex with the angiotensin-converting enzyme leads to the replacement of the latter with the porphyrin. Displacement of the angiotensin-converting enzyme from the complex with the S-protein under the action of 5-[4'-(N-methyl-1,3-benzimidazol-2-yl)phenyl]-10,15,20-tri-(N-methyl-3'-pyridyl)porphyrin triiodide is the experimental evidence for the porphyrin binding at the receptor-binding domain of the S-protein.

Keywords: SARS-CoV-2 virus; inactivation; inhibition; porphyrins; spectroscopy; spike protein.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Scheme
Scheme
1.
Fig. 1.
Fig. 1.
Results of molecular docking of N-por with the S-protein. The receptor-binding domains is shown in orange.
Fig. 2.
Fig. 2.
Changes in the Soret band range during titration of N-por (2×10–7 mol/L) with the S-protein (3.98×10–6 mol/L) in PBS. The titration was performed until the protein : porphyrin molar range 1 : 1.6 (a) and 1 : 0.75 (b).
Fig. 3.
Fig. 3.
Difference fluorescence spectra of N-por in a solution of the S-protein in PBS.
See this image and copyright information in PMC

References

    1. Harvey W.T., Carabelli A.M., Jackson B., Gupta R.K., Thomson E.C., Harrison E.M., Ludden C., Reeve R., Rambaut A., Peacock S.J., Robertson D.L. Nat. Rev. Microbiol. 2021;19:409. doi: 10.1038/s41579-021-00573-0. - DOI - PMC - PubMed
    1. Eggink, D., Andeweg, S.P., Vennema, H., van Maarseveen, N., Vermaas, K., Vlaemynck, B., Schepers, R., van Gageldonk-Lafeber, A.B., van den Hof, S., Reusken, C.B.E.M., and Knol, M.J., medRxiv., 2021. 10.1101/2021.12.20.21268121
    1. Rees-Spear C. Muir L., Griffith S.A., Heaney J., Aldon Y., Snitselaar J.L., Thomas P., Graham С., Seow J., Lee N., Rosa A., Roustan C., Houlihan C.F., Sanders R.W., Gupta R.K., Cherepanov P., Stauss H.J., Nastouli E., McCoy L.E. Cell Rep. 2021;34:108890. doi: 10.1016/j.celrep.2021.108890. - DOI - PMC - PubMed
    1. Tao K., Tzou P.L., Nouhin J., Gupta R.K., de Oliveira T., Kosakovsky Pond S.L., Fera D., Shafer R.W. Nat. Rev. Genet. 2021;22:757. doi: 10.1038/s41576-021-00408-x. - DOI - PMC - PubMed
    1. Wu C., Liu Y., Yang Y., Zhang P., Zhong W., Wang Y., Wang Q., Xu Y., Li M., Li X. Acta Pharm. Sin. (B) 2020;10:766. doi: 10.1016/j.apsb.2020.02.008. - DOI - PMC - PubMed

LinkOut - more resources